ME/CFS Evidence Browser — Classified Studies on Myalgic Encephalomyelitis

81–100 of 131 studies

E3 PreliminaryMechanismPEM unclearMechanistic

Acute Corticotropin-Releasing Factor Receptor Type 2 Agonism Results in Sustained Symptom Improvement in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Pereira, Gerard, Gillies, Hunter, Chanda, Sanjay et al.·Frontiers in systems neuroscience·2021

Researchers tested a new drug called CT38s that targets a receptor in the brain called CRFR2, which they believe may be overactive in ME/CFS. Fourteen ME/CFS patients received a single infusion of this drug, and most experienced symptom improvement that lasted at least 28 days. Side effects were mild and similar to typical ME/CFS symptoms, suggesting the drug was working on systems related to the disease.

Evidence Atlas

Evidence browser

Acute Corticotropin-Releasing Factor Receptor Type 2 Agonism Results in Sustained Symptom Improvement in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Characterization of Cortisol Dysregulation in Fibromyalgia and Chronic Fatigue Syndromes: A State-Space Approach.

High-fidelity discrete modeling of the HPA axis: a study of regulatory plasticity in biology.

Modeling diurnal hormone profiles by hierarchical state space models.

Modeling Bivariate Longitudinal Hormone Profiles by Hierarchical State Space Models.

Continuous stress promotes expression of VGF in melanotroph via suppression of dopamine.

Genetics and Gene Expression Involving Stress and Distress Pathways in Fibromyalgia with and without Comorbid Chronic Fatigue Syndrome.

A role for corticosteroid-binding globulin variants in stress-related disorders.

Increased HDAC in association with decreased plasma cortisol in older adults with chronic fatigue syndrome.

[The HPA axis in the pathogenesis of chronic fatigue syndrome].

The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome.

Model-based therapeutic correction of hypothalamic-pituitary-adrenal axis dysfunction.

Chronic fatigue syndrome and the central nervous system.

The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome.

Drug residues store in the body following cessation of use: impacts on neuroendocrine balance and behavior--use of the Hubbard sauna regimen to remove toxins and restore health.

Enhanced feedback sensitivity to prednisolone in chronic fatigue syndrome.

Antidepressant-like activity of a Kampo (Japanese herbal) medicine, Koso-san (Xiang-Su-San), and its mode of action via the hypothalamic-pituitary-adrenal axis.

Polymorphisms in genes regulating the HPA axis associated with empirically delineated classes of unexplained chronic fatigue.

Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome.

[Chronic fatigue syndrome in cardiology neurohumoral changes].

Curated Collections

Neuroinflammation Evidence

Metabolism & Mitochondria

Biomarkers

PEM-Specific Research